Switch theme
Sign up to access all valuation multiples
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical Products and Toll Manufacturing Services; and Medical Device Products. The company derives maximum revenue from Pharmaceutical Products and Toll Manufacturing Services. The company's products include consumer health, Derma, prescription, and biomedilab.
1976
1.4K+
Last FY Revenue $118M
Last FY EBITDA -$1.6M
$373M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Pyridam Farma achieved revenue of $118M and an EBITDA of -$1.6M.
Pyridam Farma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pyridam Farma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $118M | XXX | XXX | XXX |
| Gross Profit | XXX | $32.9M | XXX | XXX | XXX |
| Gross Margin | XXX | 28% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -1% | XXX | XXX | XXX |
| EBIT | XXX | -$1.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -1% | XXX | XXX | XXX |
| Net Profit | XXX | -$20.3M | XXX | XXX | XXX |
| Net Margin | XXX | -17% | XXX | XXX | XXX |
| Net Debt | XXX | $190M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Pyridam Farma's stock price is IDR 228 (or $0).
Pyridam Farma has current market cap of IDR 2.56T (or $157M), and EV of IDR 6.08T (or $373M).
See Pyridam Farma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $373M | $157M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Pyridam Farma has market cap of $157M and EV of $373M.
Pyridam Farma's trades at 3.2x EV/Revenue multiple, and -230.0x EV/EBITDA.
Equity research analysts estimate Pyridam Farma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pyridam Farma's P/E ratio is not available.
See valuation multiples for Pyridam Farma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $157M | XXX | $157M | XXX | XXX | XXX |
| EV (current) | $373M | XXX | $373M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 3.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -230.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -307.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -7.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -22.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPyridam Farma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $24K for the same period.
Pyridam Farma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pyridam Farma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pyridam Farma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $24K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pyridam Farma acquired XXX companies to date.
Last acquisition by Pyridam Farma was XXXXXXXX, XXXXX XXXXX XXXXXX . Pyridam Farma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Pyridam Farma founded? | Pyridam Farma was founded in 1976. |
| Where is Pyridam Farma headquartered? | Pyridam Farma is headquartered in Indonesia. |
| How many employees does Pyridam Farma have? | As of today, Pyridam Farma has 1.4K+ employees. |
| Is Pyridam Farma publicy listed? | Yes, Pyridam Farma is a public company listed on IDX. |
| What is the stock symbol of Pyridam Farma? | Pyridam Farma trades under PYFA ticker. |
| When did Pyridam Farma go public? | Pyridam Farma went public in 2001. |
| Who are competitors of Pyridam Farma? | Similar companies to Pyridam Farma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Pyridam Farma? | Pyridam Farma's current market cap is $157M |
| Is Pyridam Farma profitable? | Yes, Pyridam Farma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
